Want to see TNYA full AI Analyst Report?
Total Valuation
Tenaya Therapeutics has a market cap or net worth of $160.38M. The enterprise value is $47.77M.
Market Cap$160.38M
Enterprise Value$47.77M
Share Statistics
Tenaya Therapeutics has 216,998,870 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding216,998,870
Owned by Insiders23.34%
Owned by Institutions7.28%
Financial Efficiency
Tenaya Therapeutics’s return on equity (ROE) is -0.73 and return on invested capital (ROIC) is -69.39%.
Return on Equity (ROE)-0.73
Return on Assets (ROA)-0.62
Return on Invested Capital (ROIC)-69.39%
Return on Capital Employed (ROCE)-0.71
Revenue Per Employee0.00
Profits Per Employee-1.29M
Employee Count70
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Tenaya Therapeutics is ―. Tenaya Therapeutics’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio0.88
Price to Fair Value0.88
Price to FCF-1.58
Price to Operating Cash Flow-1.74
PEG Ratio0.02
Income Statement
In the last 12 months, Tenaya Therapeutics had revenue of 0.00 and earned -90.60M in profits. Earnings per share was -0.59.
Revenue0.00
Gross Profit-8.44M
Operating Income-93.33M
Pretax Income-90.60M
Net Income-90.60M
EBITDA-82.16M
Earnings Per Share (EPS)-0.59
Cash Flow
In the last 12 months, operating cash flow was -64.39M and capital expenditures -246.00K, giving a free cash flow of -64.63M billion.
Operating Cash Flow-64.39M
Free Cash Flow-64.63M
Free Cash Flow per Share-0.30
Dividends & Yields
Tenaya Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.79
52-Week Price Change22.55%
50-Day Moving Average0.77
200-Day Moving Average0.99
Relative Strength Index (RSI)46.21
Average Volume (3m)4.00M
Important Dates
Tenaya Therapeutics upcoming earnings date is Aug 12, 2026, After Close (Confirmed).
Last Earnings DateMay 6, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
Tenaya Therapeutics as a current ratio of 6.84, with Debt / Equity ratio of 9.53%
Current Ratio6.84
Quick Ratio6.84
Debt to Market Cap0.07
Net Debt to EBITDA1.09
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Tenaya Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Tenaya Therapeutics EV to EBITDA ratio is -0.23, with an EV/FCF ratio of -0.28.
EV to Sales0.00
EV to EBITDA-0.23
EV to Free Cash Flow-0.28
EV to Operating Cash Flow-0.28
Balance Sheet
Tenaya Therapeutics has $80.89M in cash and marketable securities with $10.12M in debt, giving a net cash position of $70.77M billion.
Cash & Marketable Securities$80.89M
Total Debt$10.12M
Net Cash$70.77M
Net Cash Per Share$0.33
Tangible Book Value Per Share$0.81
Margins
Gross margin is 144.89%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin144.89%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Tenaya Therapeutics is $10.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$10.33
Price Target Upside676.94% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast59.42%